Jaguar announces FDA agreement with clinical trial protocol for Canalevia-CA1

Jaguar Health has reached agreement with the U.S. Food and Drug Administration on the design and conduct of a clinical field study of Canalevia-CA1, the company’s FDA conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs, for full approval of the product. Canalevia-CA1 received conditional approval in December 2021 from the FDA for the treatment of CID in dogs and is available from multiple leading veterinary distributors in the U.S. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval.